# Working with DTCGT in the context of research

Andy Singleton Thursday, October 31, 2019





New Results

### Parkinson's disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk.

Mike A Nalls, Cornelis Blauwendraat, Costanza L Vallerga, Karl Heilbron, Sara Bandres-Ciga, Diana Chang, Manuela Tan, Demis A Kia, Alastair J Noyce, Angli Xue, Jose Bras, Emily Young, Ranier von Coelln, Javier Simon-Sanchez, Claudia Schulte, Manu Sharma, Lynne Krohn, Lasse Pihlstrom, Ari Siitonen, Hirotaka Iwaki, Hampton Leonard, Faraz Faghri, J Raphael Gibbs, Dena G Hernandez, Sonja W Scholz, Juan A Botia, Maria Martinez, Jean-Chrstophe Corvol, Suzanne Lesage, Joseph Jankovic, Lisa M Shulman, The 23andMe Research Team, System Genomics of Parkinson's Disease (SGPD) Consortium, Margaret Sutherland, Pentti Tienari, Kari Majamaa, Mathias Toft, Alexis Brice, Jian Yang, Ziv Gan-Orr, Thomas M Gasser, Peter M Heutink, Joshua M Shulman, Nicolas A Wood, David A Hinds, John R Hardy, Huw R Morris, Jacob M Gratten, Peter M Visscher, Robert R Graham, Andrew B Singleton, International Parkinson's Disease Genomics Consortium

doi: https://doi.org/10.1101/388165











New Results

### Parkinson's disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk.

Mike A Nalls, Cornelis Blauwendraat, Costanza L Vallerga, Karl Heilbron, Sara Bandres-Ciga, Diana Chang, Manuela Tan, Demis A Kia, Alastair J Noyce, Angli Xue, Jose Bras, Emily Young, Ranier von Coelln, Javier Simon-Sanchez, Claudia Schulte, Manu Sharma, Lynne Krohn, Lasse Pihlstrom, Ari Siitonen, Hirotaka Iwaki, Hampton Leonard, Faraz Faghri, J Raphael Gibbs, Dena G Hernandez, Sonja W Scholz, Juan A Botia, Maria Martinez, Jean-Chrstophe Corvol, Suzanne Lesage, Joseph Jankovic, Lisa M Shulman, The 23andMe Research Team, System Genomics of Parkinson's Disease (SGPD) Consortium, Margaret Sutherland, Pentti Tienari, Kari Majamaa, Mathias Toft, Alexis Brice, Jian Yang, Ziv Gan-Orr, Thomas M Gasser, Peter M Heutink, Joshua M Shulman, Nicolas A Wood, David A Hinds, John R Hardy, Huw R Morris, Jacob M Gratten, Peter M Visscher, Robert R Graham, Andrew B Singleton, International Parkinson's Disease Genomics Consortium

doi: https://doi.org/10.1101/388165








### 2019: Meta 5

#### Largest meta-analysis of GWAS data to date:


- meta-analysis and conditional analyses
- 37,688 cases (IPDGC+23andMe)
- 18,618 proxy-cases (UKBB)
- 1,417,791 controls (IPDGC+UKBB+23andMe)
- 11,477,547 imputed SNPs (HRC)











29,624 controls 62,037 controls 302,042 controls 935,490 controls





### Our experience

- somewhat unusual because of the subject and the companies interest
- expands beyond simple searches for risk loci for disease
  - related conditions (Mendelian randomization)
  - behaviors that influence disease risk
  - disease variability
  - sex based variation
  - bespoke replication






• How good are the data





- How good are the data
  - genetically very good
  - phenotypically not really very different than other clinical studies





- Speed
  - In general as responsive as other research groups.
  - There is a process, but the process works well.
  - Note, our area is perhaps an exception.
    Foundation/philanthropic support has been critical.
- Decisions
  - The company has its own research priorities.
  - Their own target pipeline and/or agreements.
  - Work has to be non-competitive in that regard





- Analysis and QC some barriers to what we can do
  - can look for overlap (checksums)
  - some data types not easily accessible (dosage)
- Sharing
  - the biggest challenge the current policy limits broad data sharing
  - we compartmentalize sharing of results own data sum. stat., available to download, DTCGT results, require separate agreement
- Scale
  - very very good. The capacity to include proxy cases is also substantial





### One Future?







#### YOUR EXPERIENCE FUELING RESEARCH



#### Share Your Expertise

No one understands Parkinson's better than those living with it every day. By working together, we can help shape the future of research.



#### **Participate Online**

Fox Insight easily collects selfreported data about health experiences from those with and without Parkinson's in a number of ways.



#### **Drive Genetic Insights**

Eligible individuals can help researchers gain a holistic picture of the disease by participating in a genetic sub-study powered by 23andMe.







#### Share Data

Join LunaDNA and share your data in a few steps. Your data is de-identified and encrypted to ensure privacy and security.

### Help Discovery

Researchers pay to conduct research on the aggregated data.

### Earn Benefits

Proceeds earned from research on the platform are passed back to the shareholders who shared their data.



